235 related articles for article (PubMed ID: 19238117)
1. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
di Iulio J; Fayet A; Arab-Alameddine M; Rotger M; Lubomirov R; Cavassini M; Furrer H; Günthard HF; Colombo S; Csajka C; Eap CB; Decosterd LA; Telenti A;
Pharmacogenet Genomics; 2009 Apr; 19(4):300-9. PubMed ID: 19238117
[TBL] [Abstract][Full Text] [Related]
2. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
[TBL] [Abstract][Full Text] [Related]
3. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
Haas DW; Kwara A; Richardson DM; Baker P; Papageorgiou I; Acosta EP; Morse GD; Court MH
J Antimicrob Chemother; 2014 Aug; 69(8):2175-82. PubMed ID: 24729586
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
Arab-Alameddine M; Di Iulio J; Buclin T; Rotger M; Lubomirov R; Cavassini M; Fayet A; Décosterd LA; Eap CB; Biollaz J; Telenti A; Csajka C;
Clin Pharmacol Ther; 2009 May; 85(5):485-94. PubMed ID: 19225447
[TBL] [Abstract][Full Text] [Related]
5. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
Reay R; Dandara C; Viljoen M; Rheeders M
OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
Aouri M; Barcelo C; Ternon B; Cavassini M; Anagnostopoulos A; Yerly S; Hugues H; Vernazza P; Günthard HF; Buclin T; Telenti A; Rotger M; Decosterd LA;
Drug Metab Dispos; 2016 Jan; 44(1):151-61. PubMed ID: 26553012
[TBL] [Abstract][Full Text] [Related]
7. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH
Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.
Soeria-Atmadja S; Österberg E; Gustafsson LL; Dahl ML; Eriksen J; Rubin J; Navér L
PLoS One; 2017; 12(9):e0181316. PubMed ID: 28886044
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.
Ogburn ET; Jones DR; Masters AR; Xu C; Guo Y; Desta Z
Drug Metab Dispos; 2010 Jul; 38(7):1218-29. PubMed ID: 20335270
[TBL] [Abstract][Full Text] [Related]
10. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
Maimbo M; Kiyotani K; Mushiroda T; Masimirembwa C; Nakamura Y
Eur J Clin Pharmacol; 2012 Mar; 68(3):267-71. PubMed ID: 21901344
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
[TBL] [Abstract][Full Text] [Related]
12. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
Kwara A; Lartey M; Sagoe KW; Kenu E; Court MH
AIDS; 2009 Oct; 23(16):2101-6. PubMed ID: 19779319
[TBL] [Abstract][Full Text] [Related]
13. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
[TBL] [Abstract][Full Text] [Related]
14. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
[TBL] [Abstract][Full Text] [Related]
15. Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment.
Gengiah TN; Botha JH; Yende-Zuma N; Naidoo K; Abdool Karim SS
Antivir Ther; 2015; 20(3):297-306. PubMed ID: 25318122
[TBL] [Abstract][Full Text] [Related]
16. Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.
Aurpibul L; Chotirosniramit N; Sugandhavesa P; Kosashunhanan N; Thetket S; Supindham T; Piyamongkol W; Supparatpinyo K
Curr HIV Res; 2012 Dec; 10(8):653-60. PubMed ID: 22950382
[TBL] [Abstract][Full Text] [Related]
17. CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon.
Paganotti GM; Russo G; Sobze MS; Mayaka GB; Muthoga CW; Tawe L; Martinelli A; Romano R; Vullo V
Infect Genet Evol; 2015 Oct; 35():122-6. PubMed ID: 26247717
[TBL] [Abstract][Full Text] [Related]
18. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
Elens L; Vandercam B; Yombi JC; Lison D; Wallemacq P; Haufroid V
Pharmacogenomics; 2010 Sep; 11(9):1223-34. PubMed ID: 20860463
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.
Decloedt EH; Sinxadi PZ; van Zyl GU; Wiesner L; Khoo S; Joska JA; Haas DW; Maartens G
J Antimicrob Chemother; 2019 Mar; 74(3):699-709. PubMed ID: 30535366
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.
Čolić A; Alessandrini M; Pepper MS
Drug Metab Rev; 2015 May; 47(2):111-23. PubMed ID: 25391641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
